Arima Genomics announces a new study showing that the Aventa™ lymphoma test resolves diagnostic ambiguity and guides care in ...

Authors of a recent editorial appearing in the Journal of the National Cancer Institute say opening clinical trials in follicular lymphoma (FL) to less than ideal candidates—and more like those seen ...

DelveInsight's Indolent Lymphoma Market Insights report includes a comprehensive understanding of current treatment practices ...

Lymphoma survivors with chronic fatigue participating in a multidisciplinary intervention program experienced a beneficial ...

DelveInsight’s, “Mantle Cell Lymphoma- Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and ...

CAR2119’s single-infusion approach offers cost and compliance advantages, though its competitors maintain strong commercial ...

In the global intention-to-treat population, Pola-R-CHP showed significant progression-free survival benefit over R-CHOP ...

Cancer diagnosis and treatment redefine normality, with chronic conditions like follicular lymphoma posing ongoing challenges ...

A study published in Cancer Discovery finds that combining an epigenetic therapy with an anti-PD-1 antibody, which uses the body's natural response to viral infections, shows promising results in ...

Combining an epigenetic therapy with an anti-PD-1 antibody, which uses the body's natural response to viral infections, ...

Everyday, more than 500 Central New Yorks will come to the Upstate Cancer Center or another location to get chemo, radiation ...